Luteolin mitigates proliferative vitreoretinopathy through inhibition of ERK1/2 signaling and epithelial–mesenchymal transition
Luteolin suppresses RPE cell migration and EMT both <i>in vitro</i> and <i>in vivo</i>, thereby alleviating PVR development. Its protective effect is associated with downregulation of ERK1/2 signaling. The inhibitory effects of luteolin suggest its potential as a therapeutic agent for PVR.
Authors
- Lingdan Wu (ORCID: https://orcid.org/0000-0003-3573-1455)
- Yujie Tang
- Qihua Xu
- Jinghua Chai
Institutions
- Nanchang University (CN)
- Guhua Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.3389/fphar.2026.1634617
- Primary Topic
- Retinal and Macular Surgery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- Health Commission of Jiangxi Province